← Patent-cliff monitor small molecule TAFINLAR DABRAFENIB MESYLATE
Loss of exclusivity February 2034 latest FDA-listed patent expiry
Company Novartis → See this company's full patent-cliff portfolio Drug detail Brand name TAFINLAR Active ingredient DABRAFENIB MESYLATE Strength EQ 75MG BASE Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval May 2013 Marketing status RX
Listed patents Patent Expires Type 10869869*PED February 2034 — 10869869 August 2033 use U-3185 8952018*PED April 2031 — 8703781*PED April 2031 — 8703781 October 2030 substance, product 8952018 October 2030 use U-2027 7994185*PED July 2030 — 8415345*PED July 2030 — 8415345 January 2030 substance, product 7994185 January 2030 substance, product 9233956*PED November 2029 — 9233956 May 2029 use U-2032
Regulatory exclusivity Code Expires PED September 2030 ODE-428 March 2030 PED September 2026 I-908 March 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.